Document is current

Article History

Received: 27 February 2025

Accepted: 20 May 2025

First Online: 23 June 2025

Declarations

:

: Emma Guttman-Yassky is a consultant for: AbbVie, Almirall, Amgen, Asana BioSciences, Boehringer Ingelheim, Cara Therapeutics, Celgene, Concert Pharmaceuticals, DBV Technologies, Dermira, DS Biopharma, Eli Lilly and Company, EMD Serono, Escalier Biosciences, Galderma, Glenmark Pharmaceuticals, Kyowa Kirin, LEO Pharma, Mitsubishi Tanabe, Pfizer, RAPT Therapeutics, Regeneron, Sanofi, Sienna Biopharmaceuticals, and UNION Therapeutics; and reports institute grants for research from: AbbVie, Almirall, Amgen, AnaptysBio, Asana BioSciences, Boehringer Ingelheim, Celgene, Dermavant, DS Biopharma, Eli Lilly and Company, Galderma, Glenmark Pharmaceuticals, Innovaderm Research, Janssen, Kiniska Pharmaceuticals, Kyowa Kirin, LEO Pharma, Novan, Pfizer, Ralexar Therapeutics, Regeneron, Sienna Biopharmaceuticals, UCB Pharma, and UNION Therapeutics; Stephan Weidinger is a speaker, advisory board member, and/or investigator for: AbbVie, Almirall, Eli Lilly and Company, Galderma, Kymab, LEO Pharma, Pfizer, Regeneron, and Sanofi; and has received research grants from: LEO Pharma, Pfizer, and Sanofi; Eric L. Simpson reports personal fees from: AbbVie, Amgen, Arena Pharmaceuticals, ASLAN Pharmaceuticals, Boston Consulting Group, Collective Acumen, Dermira, Eli Lilly and Company, Evidera, Excerpta Medica, Forte Biosciences, Galderma, GlaxoSmithKline, Incyte Corporation, Janssen, Kyowa Kirin, LEO Pharma, Medscape, Merck, Pfizer, Physicians World, Regeneron, Roivant Sciences, Sanofi Genzyme, Trevi Therapeutics, Valeant Pharmaceuticals, and WebMD; and reports grants from or serves in a Principal Investigator role for: AbbVie, Amgen, Arcutis, ASLAN Pharmaceuticals, CorEvitas, Dermavant, Dermira, Eli Lilly and Company, Incyte Corporation, Kymab, Kyowa Hakko Kirin, LEO Pharma, Pfizer, Regeneron, Sanofi, and TARGET; Melinda Gooderham has been an investigator, speaker, consultant, or advisory board member for: AbbVie, Akros Pharma, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermavant, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Incyte Corporation, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB Pharma, and Valeant Pharmaceuticals/Bausch Health; Alan D. Irvine is a speaker, advisory board member, and/or investigator for: AbbVie, Almirall, Connect BioPharma, Eli Lilly and Company, LEO Pharma, OM Pharma, Pfizer, RAPT Therapeutics, Regeneron, and Sanofi; Lynda Spelman has been a consultant, and/or scientific adviser, and/or investigator, and/or scientific officer, and/or speaker for: AbbVie, Akesobio, Alphyn Biologics, Amgen, Anacor, Ascend, Aslan, Astellas, AstraZeneca, Blaze Bioscience, Bristol Myers Squibb, Boehringer Ingelheim, Botanix, Celgene, Connect Biopharmaceuticals Australia, Dermira, Eli Lilly and Company, Evelo Biosciences, Galderma, Genentech, GSK, Hexima, Immunic Therapeutics, Invion, Janssen, Kiniksa Pharmaceuticals, Kobiolab, LEO Pharma, Lipidio, Mayne, Medimmune, Merck (MSD), Merck Serono, Novartis, Otsuka, Pfizer, Phosphagenics, Photon MD, Regeneron, Reistone, Roche, Samumed, Sanofi Genzyme, SHR, Sun Pharma ANZ, Trius, UCB Pharma, Vyne Therapeutics and Zai Lab; Jonathan I. Silverberg has received grants and/or personal fees from: AbbVie, AFYX Therapeutics, Almirall, Arena Pharmaceuticals, Asana BioSciences, Bluefin Biomedicine, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Incyte Corporation, Kiniksa Pharmaceuticals, LEO Pharma, Luna Pharma, Menlo Therapeutics, Novartis, Pfizer, RAPT Therapeutics, Regeneron, and Sanofi; Hany Elmaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Chaoran Hu, Fan Emily Yang, and Evangeline Pierce are employees and stockholders of: Eli Lilly and Company; Laia Bardolet is an employee of Almirall; Diamant Thaçi has received personal fees from: AbbVie, Almirall, Amgen, Asana BioSciences, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Janssen Cilag, Kyowa Kirin, LEO Pharma, Novartis, Pfizer, Regeneron, Sandoz, Sanofi, and UCB Pharma; and has received grants from: AbbVie, LEO Pharma, and Novartis.

: The ADvocate1, ADvocate2, ADhere, and ADjoin clinical trials were undertaken in accordance with ethical principles of the Declaration of Helsinki, Council for International Organizations of Medical Sciences, and Good Clinical Practice guidelines. All investigation sites received approval from the appropriate authorized institutional review board or ethics committee. Informed consent was obtained from all patients before study procedures were initiated. For patients considered to be minors, written consent of the parent or legal guardian, as well as the assent of the minor, was obtained.